Godavari Biorefineries Ltd

- Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries. - The company targets a significant increase in revenue, aiming for close to INR 3,000 crores topline by 2029 with 10-11% EBITDA margin. - Expansion of bio-based chemicals, including specialty chemicals and bio-based monomers, is a key driver for high-margin growth. - Increasing ethanol blending mandates (E20 achieved 5 years ahead of schedule) and potential introduction of flex fuel vehicles will boost ethanol demand. - Continuous innovation and co-creation with customers to develop green transition products underpin growth. - Consumer brand Jivana has crossed INR 100 crores sales in 9 months and is expected to broaden distribution and product portfolio. - The company plans disciplined execution, capital efficiency, and portfolio optimization for sustainable long-term value creation.

- Godavari Biorefineries aims to achieve a 3x EBITDA growth by FY29, targeting INR 3000 crores topline with 10-11% EBITDA margin (Page 13). - The company is optimistic about long-term growth driven by green transition, ethanol blending (E20 achieved 5 years ahead of schedule), and expanding bio-based chemicals (Pages 14-16). - Capacity expansion in grain-based ethanol distillery expected to improve utilization from next quarter onwards (Pages 7, 13). - Focus on portfolio diversification and new bio-based specialty chemicals to drive better margins and capacity utilization (Pages 12-14). - Continued cost optimization, improved product mix, and operating leverage led to a 13.8% EBITDA growth in Q3 FY26, with margins improving by 97 bps to 9.8% (Page 3). - Company maintains a bullish stance on the sector for medium to long term, emphasizing capital efficiency and innovation (Pages 2-4).

- The transcript does not explicitly mention the current or expected order book or pending orders for Godavari Biorefineries Limited. - The company has received binding supply obligations for ethanol volumes through OMC tenders for the ethanol supply year. - Operational and financial preparations are underway to service these mandated volumes despite margin pressures from rising cane costs. - The grain-based ethanol facility commissioning is delayed but expected by next quarter, which will support their capacity to meet orders. - The company is focusing on adding capacity and debottlenecking in bio-based chemicals and ethanol to support growth. - There is an active strategy to co-create specialized bio-based chemicals with customers, involving signed MOUs (e.g., with Synthomer for bio-based butanol), indicating ongoing and potential future orders in specialty chemicals. - Overall, no specific numeric order book or pending orders data is disclosed.

- The transcript from the document does not mention any plans for current or future fundraising through debt or equity. - The company is focused on capacity expansion, particularly in grain-based ethanol and bio-based chemicals, but specific financing details are not discussed. - Capital expenditure guidance includes an estimated INR 325 crores capex by FY29, with 75% allocated to bio-based chemicals and 25% to ethanol, implying internal funding or existing resources are being utilized. - No explicit mention of raising fresh equity or taking on new debt is made during the call. - The company emphasizes cash flow discipline and managing working capital but without concrete plans for external fundraising stated.

- Godavari Biorefineries is investing in capacity expansion, notably: - Adding a grain-based (maize) ethanol distillery facility, with commissioning expected next quarter due to some equipment delays. - Continuing investments in bio-based specialty chemicals capacity through debottlenecking and expansions. - Total planned capex is estimated at INR 325 crores by FY29, with approximately 75% allocated to bio-based chemicals and 25% to ethanol. - Strategic investments include: - Licensing deal with Catalyxx for bio-based butanol production. - Collaboration with Synthomer to commercialize bio-based butyl acrylate. - Pilot plant development for dimethyl ether (DME) technology in partnership with the Institute of Chemical Technology. - Research into cancer biology molecules and bio-based chemical products as part of ongoing innovation pipelines. - Focus on balancing capital allocation to ensure predictable earnings and managing feedstock and regulatory risks through multi-feedstock distilleries.